GeoWealth Management LLC Purchases 72 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

GeoWealth Management LLC increased its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 342.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 93 shares of the medical research company’s stock after purchasing an additional 72 shares during the period. GeoWealth Management LLC’s holdings in Bio-Rad Laboratories were worth $31,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Venturi Wealth Management LLC boosted its stake in Bio-Rad Laboratories by 2,175.0% during the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock worth $30,000 after buying an additional 87 shares in the last quarter. Picton Mahoney Asset Management boosted its position in shares of Bio-Rad Laboratories by 55.6% during the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 35 shares in the last quarter. Asset Planning Inc acquired a new stake in shares of Bio-Rad Laboratories during the 4th quarter valued at about $33,000. UMB Bank n.a. increased its stake in Bio-Rad Laboratories by 41.6% in the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock valued at $36,000 after acquiring an additional 32 shares during the period. Finally, Cape Investment Advisory Inc. acquired a new position in Bio-Rad Laboratories in the fourth quarter worth about $38,000. 65.24% of the stock is currently owned by institutional investors.

Bio-Rad Laboratories Stock Down 3.0 %

Shares of BIO opened at $242.22 on Friday. The company has a market capitalization of $6.78 billion, a P/E ratio of -3.72 and a beta of 1.12. Bio-Rad Laboratories, Inc. has a one year low of $215.38 and a one year high of $387.99. The business’s 50 day simple moving average is $251.03 and its 200-day simple moving average is $308.28. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. As a group, sell-side analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BIO has been the topic of several analyst reports. StockNews.com lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, February 17th. Royal Bank of Canada reiterated an “outperform” rating and issued a $481.00 price target on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Finally, Wells Fargo & Company cut their price objective on Bio-Rad Laboratories from $320.00 to $270.00 and set an “equal weight” rating for the company in a report on Thursday, April 17th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $380.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.